logo
Share SHARE
FONT-SIZE Plus   Neg

Baxter, Halozyme Issue Update On HyQ Biologics License Application

Baxter International Inc. (BAX: Quote) and Halozyme Therapeutics, Inc. (HALO: Quote) announced that the U.S. Food and Drug Administration, or FDA, is requesting additional information to complete its review of the HyQ Biologics License Application, or BLA.

Both the companies will work closely together to develop studies to provide additional data to address concerns raised by the FDA related to the long-term chronic use of HyQ. At present, the companies expect to participate in a meeting of the FDA's Blood Products Advisory Committee concerning the agency's request for additional data. The companies expect these requests to require additional time to complete and to delay their anticipated regulatory review and approval timeline.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Comcast Corp found itself in an unsavory situation after a customer's name on a bill was changed from Ricardo to 'A**hole', ostensibly by a disgruntled employee who tried to get the customer to retain her current cable service and sign a two-year contract. Blockbuster sales of big-screen iPhones during the holiday quarter has helped tech giant Apple Inc. (AAPL) to tie with Samsung to become the world's largest smartphone vendor. Both Apple and Samsung sold 74.5 million smartphones during the December quarter, according to research firm Strategy Analytics.... Toyota Motor Sales, U.S.A., Inc., a unit of Japanese auto giant Toyota Motor Corp. (TYT.L, TM), said it is recalling 52,000 - 2011-2012 Avalon sedans in the U.S. due to a wiring problem that increases risk of fire. The company says cargo in trunk of the affected cars could contact one of the audio...
comments powered by Disqus
Follow RTT